Company description: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Job description: Join Us in Changing Lives At? OXB, our people are at the heart of everything we do.?Were?on a mission to enable life-changing therapies to reach patients around the worldand?were?looking for passionate individuals who embody our core values every day:? Responsible, Responsive, Resilient, and Respectful. We are currently hiring a Principal Veeva System Administrator to join our Information Systems (IS) team. In this role, you will take technical ownership of the Global Veeva Vault environment, oversee system configurations and software updates while ensuring platform stability, data integrity, and adherence to the system change management processes, playing a key part in advancing our mission and making a real difference. Your responsibilities in this role would be: Administering, configuring, and maintaining Veeva Vault to support business operations and compliance needs Acting as an internal & external Veeva technical expert with detailed in-depth knowledge of the system configurations and their relationship to ensure compliance with GMP Partnering with OXB Validation department to ensure the Veeva Vault system retains its validated status throughout its lifecycle Owning the solution strategy for the delivery of system updates and enhancements Advising global operations leadership on the systems operational status regarding system updates and releases During system updates, working with the supplier (Veeva) to review system release notes and leading the assessment of risk to our system configuration and validation status. Raising change controls within the OXB QMS to support the implementation of system updates Supporting new releases as prioritised with the Veeva Product Owner In collaboration with the Veeva Product Owner, fostering and considering the impact of continuous improvement of Veeva capabilities We are looking for: A degree level education in Information Systems, Computer Science, Life Sciences, or equivalent level work experience Experience of administering a Veeva Vault platform Familiarity with GxP and validation processes in regulated environments Experience with change control, configuration management, and release management processes Veeva Vault Administrator certification (preferred) About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than?30?years of experience in viral vectors; the driving force behind?the majority of?gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing?expertise?in lentivirus, adeno-associated virus (AAV)?and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory?expertise. Why Join Us? ???Competitive total reward packages ???Wellbeing programmes?that support your mental and physical health ???Career development opportunities?to help you grow and thrive ???Supportive, inclusive, and collaborative culture ???State-of-the-art labs and manufacturing facilities ???A company that lives its values:? Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At?OXB,?were?future-focused and growing fast. We succeed togetherthrough passion, commitment, and teamwork. Ready to Make a Difference? Collaborate. Contribute. Change lives. We offer: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.